Neuphoria Therapeutics Inc. (NEUP)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.27
- As of
Kresmion compiles this page from NEUP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Neuphoria Therapeutics Inc. (NEUP): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-16.
See the full NEUP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NEUP on one page. Preview it with sample data, then open it live with a free account.
Preview the NEUP dossierActive events for NEUP
- mediumEarnings below estimates
Q4-2026: Missed consensus by 66.3%, EPS $-0.95 vs $-0.5712 estimate
- medium13F: new position
CITADEL ADVISORS LLC new position in NEUP
- medium13F: new position
RENAISSANCE TECHNOLOGIES LLC new position in NEUP
- mediumEarnings below estimates
Q4-2025: Missed consensus by 173.3% - EPS $-5.79 vs $-2.1182 estimate
- mediumEarnings below estimates
Q1-2026: Missed consensus by 225.9% - EPS $-4.41 vs $-1.3532 estimate
FREE, NO ACCOUNT
Every event on NEUP, as it fires
You are seeing 5 of 7 events recorded on NEUP since 2026-05-31.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, NEUP
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on NEUP
NEUP against its peers
NEUP's operating margin of -1401.1% ranks in the 50th percentile of 8 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | NEUP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.2M USD | 1.0M USD | 55 | 9 |
| Revenue YoY | -92.5% | n/a | n/a | 2 |
| Operating margin | -1401.1% | -1583.6% | 50 | 8 |
| Net margin | -1145.7% | -388.3% | 39 | 8 |
| Return on equity | -54.7% | -114.4% | 83 | 14 |
| 1 year | -43.9% | -64.1% | 56 | 16 |
Peers (18): KYNB, BOLT, MRKR, ALLR, ABOS, MCRB, ACTU, NCEL, HEPA, ATYR, ESLA, INTI, DYAI, CNTX, PLUR, SYBX, AKTX, ADIL. Left out: RADX (no annual filing), CTXR (no annual filing), CKDXF (period gap), HOOK.D (period gap), VICP (period gap), FNCHQ (period gap), QNTM (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (NEUP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in NEUP on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on NEUP in the last 180 days.
Upstream: SEC EDGAR filings for NEUP
Kresmion, "Neuphoria Therapeutics Inc. (NEUP) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/NEUP. Upstream data: SEC EDGAR filings for NEUP.
Link to this data (HTML):
<a href="https://kresmion.com/research/NEUP">Neuphoria Therapeutics Inc. (NEUP) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow NEUP on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to NEUP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.